Anti-Growth-hormone-releasing hormone ELISA Kit (DEIABL211)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

serum, plasma
Species Reactivity
Intended Use
The Anti-Growth-hormone-releasing hormone (GHRH) ADA ELISA kit is designed for the qualitative determination of antibodies to Growth-hormonereleasing hormone (GHRH) in serum and plasma. Our ELISA-based kits combine a fast, user-friendly format with a sensitive and specific assay. This assay designed to detect IgG, IgM and IgA antibodies specific to Growth-hormone-releasing hormone (GHRH).
Store the unopened kit at 2-8°C.
Intra-assay precision (CV%): 4% - 8%. Inter-assay precision (CV%): 7%.
Detection Range
The drug tolerance is up to 100 ng/mL of Growth-hormone-releasing hormone (GHRH).
Detection Limit
67 ng/mL


Have you cited DEIABL211 in a publication? Let us know and earn a reward for your research.

Related Products

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Short-Term Estradiol Supplementation Potentiates Low-Dose Ghrelin Action in the Presence of GHRH or Somatostatin in Older Women


Authors: Norman, Catalina; Rollene, Nanette; Weist, Suanne M.; Wigham, Jean R.; Erickson, Dana; Miles, John M.; Bowers, Cyril Y.; Veldhuis, Johannes D.

Context: Ghrelin is a potent gastric-derived GH-releasing peptide. How ghrelin interacts with sex steroids, GHRH, and somatostatin (SS) is not known. Objective: Our objective was to test the hypotheses that ghrelin's interactions with GHRH (synergistic) and SS (disinhibitory) are ghrelin dose-dependent and amplified by estrogen. Subjects, Setting, and Design: Healthy postmenopausal women were treated with placebo (n = 12) or 17 beta-estradiol (E-2) (n = 12) at the Center for Translational Science Activities in a randomized double-blind prospective study. Methods: Ghrelin dose-dependence was assessed by nonlinear curve fitting of the relationship between deconvolved GH secretory-burst mass and 5 randomly ordered ghrelin doses (0, 0.03, 0.135, 0.6, and 2.7 mu g/kg bolus iv) during saline, GHRH, and SS infusion. Results: Under placebo, neither GHRH nor SS altered the ED50 of ghrelin (range 0.64-0.67 mu g/kg). Under E-2 (median E-2 88 pg/mL), the ED50 of ghrelin declined in the presence of GHRH to 0.52 mu g/kg. In contrast, the efficacy of ghrelin rose markedly during GHRH vs saline exposure with and without E-2: placebo and saline 52 +/- 1.0 vs GHRH 173 +/- 3.8 mu g/L; and E-2 and saline 56 +/- 0.90 vs GHRH 174 +/- 3.7 mu g/L. Sensitivity to ghrelin was similar under all conditions. Summary: Short-term E-2 supplementation in postmenopausal women reduces the ED50 (increases the potency) of ghrelin when GHRH is present, without altering ghrelin efficacy (maximal effect) or hypothalamo-pituitary sensitivity (slope of dose response) to ghrelin. The data suggest possible physiological interactions among sex steroids (endogenous), ghrelin, and GHRH during E-2 replacement in postmenopausal women.

GHRH-mediated transactivation of EGFR in human androgen-independent prostate cancer cells


Authors: Munoz-Moreno, L.; Arenas, M. I.; Prieto, J. C.; Carmena, M. J.; Schally, A. V.; Bajo, A. M.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket